EKR Therapeutics and the sweet taste of “re-acquisition”
A few months ago, I wrote about the intriguing trend toward “re-launching” biotech startups that had been recently acquired by Big Pharma or Big Biotech — minus, of course, whatever promising drug candidates had prompted the acquisition in the first place. Now an entrepreneur has taken the logic one step further, having just re-acquired a drug from the troubled biotech that bought out his previous startup three years earlier.
EKR Therapeutics, a Cedar Knolls, N.J., specialty… Continue Reading